Valuation
- Market cap
- 346,486,000
- Revenue TTM
- $0
- Net income TTM
- $-158,350,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 345,800
- Avg volume
- 272,696
- Day's range
- $4.30 – $4.55
- Shares out
- 80,205,000
- Stochastic %K
- 2%
- Beta
- 0.39
- Analysts
- Sell
- Price target
- $8.50
Company profile
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-58...
Show more
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 857 284 8891
- Website
- https://ateapharma.com
- Address
- 225 Franklin Street, Suite 2100, Boston, United States
Latest news
No headlines yet.
